Paper32130708
Ovarian Cancer Biomarkers: Moving Forward in Early Detection.
Bonifácio VDB. Adv Exp Med Biol, 2020. Cited by 82 papers, by iCite.
Cite this record
ConductScience Library. Ovarian Cancer Biomarkers: Moving Forward in Early Detection. Papers, record 32130708. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32130708
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Biomarkers, Tumor | Major topic |
| Early Detection of Cancer | Major topic |
| Ovarian Neoplasms | Major topic |
| CA-125 Antigen | |
| Female | |
| Humans | |
| Proteomics |
Source PubMed
References67
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15199385 | Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer. | Br J Cancer | 2004 | https://conductscience.org/library/papers/15199385 | PubMed |
| 2 | 16220531 | Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. | Proteomics | 2005 | https://conductscience.org/library/papers/16220531 | PubMed |
| 3 | 29662629 | Pre-diagnostic biomarkers of metabolic dysregulation and cancer mortality. | Oncotarget | 2018 | https://conductscience.org/library/papers/29662629 | PubMed |
| 4 | 16674097 | Comparative proteomics of ovarian epithelial tumors. | J Proteome Res | 2006 | https://conductscience.org/library/papers/16674097 | PubMed |
| 5 | 12488461 | The human plasma proteome: history, character, and diagnostic prospects. | Mol Cell Proteomics | 2002 | https://conductscience.org/library/papers/12488461 | PubMed |
| 6 | 19007973 | Urinary levels of Bcl-2 are elevated in ovarian cancer patients. | Gynecol Oncol | 2009 | https://conductscience.org/library/papers/19007973 | PubMed |
| 7 | 17532030 | Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. | Gynecol Oncol | 2007 | https://conductscience.org/library/papers/17532030 | PubMed |
| 8 | 10228898 | CA 125: the past and the future. | Int J Biol Markers | 1998 | https://conductscience.org/library/papers/10228898 | PubMed |
| 9 | 15266667 | Discovery of ovarian cancer biomarkers in serum using NanoLC electrospray ionization TOF and FT-ICR mass spectrometry. | Dis Markers | 2003 | https://conductscience.org/library/papers/15266667 | PubMed |
| 10 | 29430218 | Metabolomic characterization of experimental ovarian cancer ascitic fluid. | Metabolomics | 2017 | https://conductscience.org/library/papers/29430218 | PubMed |
| 11 | 16428467 | Ovarian cancer biomarkers in urine. | Clin Cancer Res | 2006 | https://conductscience.org/library/papers/16428467 | PubMed |
| 12 | 25225597 | In 2014, can we do better than CA125 in the early detection of ovarian cancer? | World J Biol Chem | 2014 | https://conductscience.org/library/papers/25225597 | PubMed |
| 13 | 26970494 | Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses. | Am J Obstet Gynecol | 2016 | https://conductscience.org/library/papers/26970494 | PubMed |
| 14 | 29038145 | Oncometabolites: A New Paradigm for Oncology, Metabolism, and the Clinical Laboratory. | Clin Chem | 2017 | https://conductscience.org/library/papers/29038145 | PubMed |
| 15 | 27381498 | Level of HE4 is Correlated with Diagnosis of Struma Ovarii: A Case Report. | Am J Case Rep | 2016 | https://conductscience.org/library/papers/27381498 | PubMed |
| 16 | 20071014 | Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer. | Gynecol Oncol | 2010 | https://conductscience.org/library/papers/20071014 | PubMed |
| 17 | 25736266 | Proteomics of ovarian cancer: functional insights and clinical applications. | Cancer Metastasis Rev | 2015 | https://conductscience.org/library/papers/25736266 | PubMed |
| 18 | 23485231 | Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. | Eur J Cancer | 2013 | https://conductscience.org/library/papers/23485231 | PubMed |
| 19 | 30429787 | Tumor Microenvironment Targeted Nanotherapy. | Front Pharmacol | 2018 | https://conductscience.org/library/papers/30429787 | PubMed |
| 20 | 29244844 | Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers. | PLoS One | 2017 | https://conductscience.org/library/papers/29244844 | PubMed |
Cited by69
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 82 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42973469 | A modified ovarian-adnexal reporting and data system ultrasound for differentiating ovarian carcinoma: integration of the risk of malignancy algorithm into the American College of Radiology's O-RADS US framework. | Front Oncol | 2026 | https://conductscience.org/library/papers/42973469 | PubMed |
| 42601376 | The phosphoproteome of ovarian carcinoma delineates signaling signatures and potentially druggable targets across histotype stages. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/42601376 | PubMed |
| 42451690 | Construction of a Near-Infrared Viscosity Fluorescent Probe Targeting Mitochondria and Study on Its pH-Coordinated Effect. | Molecules | 2026 | https://conductscience.org/library/papers/42451690 | PubMed |
| 42350421 | Potent anti-tumor activity of CD98hc-targeted antibody-drug conjugates in ovarian cancer. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42350421 | PubMed |
| 41969514 | Low LAMA2 expression may affect drug resistance and prognosis in ovarian cancer via positive LGR5 coexpression. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/41969514 | PubMed |
| 41772713 | Molecular and cellular landscapes of the immune microenvironment and multiomic biomarker-sets in platinum-resistant recurrent ovarian cancers. | J Ovarian Res | 2026 | https://conductscience.org/library/papers/41772713 | PubMed |
| 41731152 | Au-decorated NiYFe-LDH/MWCNT nanohybrid-based high-performance immunosensor for ultrasensitive electrochemical detection of cancer antigen 125. | Mikrochim Acta | 2026 | https://conductscience.org/library/papers/41731152 | PubMed |
| 41376855 | Platinum-resistant ovarian cancer: From mechanisms to treatment strategies. | Genes Dis | 2026 | https://conductscience.org/library/papers/41376855 | PubMed |
| 41018112 | 6-gingerol promotes apoptosis of ovarian cancer cells through miR-506/Gli3 signaling pathway activation. | Front Oncol | 2025 | https://conductscience.org/library/papers/41018112 | PubMed |
| 40943317 | The OvarianTag™ Biomarker Panel Emerges as a Prognostic Tool to Guide Clinical Decisions in Cisplatin-Based Treatment of Epithelial Ovarian Cancer. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40943317 | PubMed |
| 40778374 | Unveiling histotype-specific biomarkers in ovarian carcinoma using proteomics. | Mol Ther Oncol | 2025 | https://conductscience.org/library/papers/40778374 | PubMed |
| 40605080 | The role and therapeutic value of NUSAP1 in human cancers. | J Transl Med | 2025 | https://conductscience.org/library/papers/40605080 | PubMed |
| 40463490 | Diagnostic Value of PET/CT for Ovarian Cancer Recurrence or Metastasis in Postoperative Patients With Elevated Serum CA125 Levels: A Systematic Review and Meta-Analysis. | Cancer Innov | 2025 | https://conductscience.org/library/papers/40463490 | PubMed |
| 40372993 | Characterization of small extracellular vesicles from ovarian cancer patients and pre-diagnostic patient samples: Evidence from the Danish blood donor study. | PLoS One | 2025 | https://conductscience.org/library/papers/40372993 | PubMed |
| 40358150 | On the Quest for Biomarkers: A Comprehensive Analysis of Modified Nucleosides in Ovarian Cancer Cell Lines. | Cells | 2025 | https://conductscience.org/library/papers/40358150 | PubMed |
| 40038842 | Investigation of the mechanism by which FOXJ2 inhibits proliferation, metastasis and cell cycle progression of ovarian cancer cells through the PI3K/AKT signaling pathway. | Eur J Med Res | 2025 | https://conductscience.org/library/papers/40038842 | PubMed |
| 39839766 | Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer. | Front Oncol | 2024 | https://conductscience.org/library/papers/39839766 | PubMed |
| 39744561 | MiR-675 Inhibits Primary Ovarian Tumor Growth and Metastasis by Suppressing EMT and TGFβ Signaling. | J Cancer | 2025 | https://conductscience.org/library/papers/39744561 | PubMed |
| 39588300 | Drug resistance biomarkers in ovarian cancer: a bibliometric study from 2017 to 2022. | Front Oncol | 2024 | https://conductscience.org/library/papers/39588300 | PubMed |
| 39479573 | Sensitive and Cost-Effective Tools in the Detection of Ovarian Cancer Biomarkers. | Anal Sci Adv | 2024 | https://conductscience.org/library/papers/39479573 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| MUC16 | 94025 | PubTator's text mining | https://conductscience.org/library/genes/94025 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32130708
GET https://conductscience.org/api/papers/v1/32130708/references?page=2